Does the NHS fund the Mounjaro weight-loss jab — and who qualifies?

Who does the NHS actually fund Mounjaro for right now?

The short answer: a relatively small group of people, at least for now. NHS eligibility for Mounjaro is governed by NICE Technology Appraisal 1026, published in December 2024 and updated in September 2025. Under the current phase, which started in June 2025, funding is available to adults with a BMI of 40 or above who also have four or more of five specified weight-related conditions: type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease. That is a deliberately narrow starting group.

A second cohort opened in June 2026, extending funding to adults with a BMI of 35 to 39.9 who also have four or more of those same conditions. A further expansion (BMI 40 or above with three qualifying conditions) is expected around March 2027. BMI thresholds are reduced by 2.5 kg/m² for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds throughout all phases. Meeting the numbers does not guarantee a prescription; your GP practice must also have opted into the 2026/27 QOF arrangements, and every patient is expected to engage with wraparound diet and activity support. More detail on what NHS access involves in practice is worth reading if you are trying to work out whether you qualify.

If you sit just outside those thresholds (a BMI of 38 with three conditions, for instance) you are not eligible under the current NHS framework, even if tirzepatide would benefit you clinically. That gap is real, and it is why many people are exploring private routes, including those who want to buy the Mounjaro jab through a regulated online pharmacy rather than wait.

Why is NHS funding for the Mounjaro jab being phased rather than opened all at once?

Demand is the honest answer. Obesity affects more than a quarter of adults in England, and NICE's appraisal of tirzepatide (TA1026) found it cost-effective only when directed at the highest-need patients first. The NHS England commissioning model is designed to bring the medicine into primary care incrementally, managing supply, training prescribers, and building the wraparound lifestyle support that NICE requires alongside the medicine.

From 1 April 2026, GP practices can prescribe Mounjaro directly under the new QOF contract, which is a significant shift from the previous specialist-only route. But participation is voluntary for practices, so your surgery may or may not be set up to do this yet. Waiting times at those that are involved can still be considerable.

The phased approach also reflects the supply picture. Eli Lilly raised UK list prices substantially from September 2025 (the highest dose's list price moved from around £122 to around £330 per four-week pen, as widely reported) which has affected how commissioners and patients alike are budgeting. If you want to understand how Mounjaro costs compare across private providers, that context is worth having before you start looking.

If you don't qualify for NHS funding, what does the private route look like?

A private Mounjaro prescription is a legitimate option for people who are eligible clinically but do not meet NHS criteria, or who would rather not wait. The process starts with a consultation, at a regulated service like the Mounjaro treatment page at nume, this is free and reviewed the same day by a GPhC-registered Independent Prescriber. No algorithm makes the clinical call; a named prescriber reads your answers.

Once approved, dispatch is same-day for orders placed before midday on a weekday. Your pen arrives the next working day with DPD, in plain unbranded packaging with a tracking link sent to your phone. The pen itself is a pre-filled KwikPen, each contains four weekly doses, chilled for transport. Everything is sourced through the licensed UK supply chain from Eli Lilly's authorised distributors.

It is worth being clear-eyed about legitimacy. The MHRA has warned repeatedly about counterfeit tirzepatide pens being sold online and via social media, including the October 2025 raid on a manufacturing site in Northampton producing fake pens. Before using any online pharmacy, verify it at the GPhC register. A pharmacy offering these medicines without a clinical assessment is a red flag, full stop. You can also read about what the NHS says about Mounjaro's side effects to go into any consultation well-informed.

Should you wait for NHS funding or explore private treatment now?

That is genuinely a personal decision, and one worth thinking through carefully. If you clearly meet the current NHS criteria (BMI 40-plus, four qualifying conditions) it is worth speaking to your GP first. NHS treatment is free and comes with structured support. The question of whether you can get Mounjaro on the NHS for weight loss has a more nuanced answer than many people expect, so checking your own eligibility properly is the right starting point.

If you are outside the current thresholds, or your GP practice is not yet set up to prescribe under the new arrangements, private treatment through a GPhC-registered pharmacy means you can start now rather than waiting for a criteria expansion that may be months away. There is no subscription and no auto-renewal at a service like ours, every repeat order is reviewed again by a prescriber before anything is sent.

One honest note on cost: private treatment is not cheap, and the cheapest private option is not automatically the right one for a prescription medicine. The relevant measure is whether the supply chain is verified, the prescriber is real, and the clinical oversight is ongoing. If you have questions before starting, our FAQs cover the most common ones. When you are ready, start your free consultation and a prescriber will review your answers the same day.